GeoVax Labs Statistics
Total Valuation
GeoVax Labs has a market cap or net worth of $3.33 million. The enterprise value is $1.08 million.
Important Dates
The last earnings date was Wednesday, April 15, 2026.
| Earnings Date | Apr 15, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
GeoVax Labs has 2.89 million shares outstanding. The number of shares has increased by 361.94% in one year.
| Current Share Class | 2.89M |
| Shares Outstanding | 2.89M |
| Shares Change (YoY) | +361.94% |
| Shares Change (QoQ) | +113.74% |
| Owned by Insiders (%) | 0.13% |
| Owned by Institutions (%) | 9.49% |
| Float | 2.89M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 1.34 |
| Forward PS | n/a |
| PB Ratio | 0.53 |
| P/TBV Ratio | 0.87 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 0.44 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 2.74, with a Debt / Equity ratio of 0.22.
| Current Ratio | 2.74 |
| Quick Ratio | 1.59 |
| Debt / Equity | 0.22 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -483.79% and return on invested capital (ROIC) is -278.37%.
| Return on Equity (ROE) | -483.79% |
| Return on Assets (ROA) | -186.57% |
| Return on Invested Capital (ROIC) | -278.37% |
| Return on Capital Employed (ROCE) | -491.22% |
| Weighted Average Cost of Capital (WACC) | 20.08% |
| Revenue Per Employee | $146,420 |
| Profits Per Employee | -$1.26M |
| Employee Count | 17 |
| Asset Turnover | 0.34 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -94.38% in the last 52 weeks. The beta is 3.80, so GeoVax Labs's price volatility has been higher than the market average.
| Beta (5Y) | 3.80 |
| 52-Week Price Change | -94.38% |
| 50-Day Moving Average | 1.52 |
| 200-Day Moving Average | 9.62 |
| Relative Strength Index (RSI) | 33.26 |
| Average Volume (20 Days) | 95,429 |
Short Selling Information
The latest short interest is 252,981, so 8.75% of the outstanding shares have been sold short.
| Short Interest | 252,981 |
| Short Previous Month | 265,418 |
| Short % of Shares Out | 8.75% |
| Short % of Float | 8.76% |
| Short Ratio (days to cover) | 3.88 |
Income Statement
In the last 12 months, GeoVax Labs had revenue of $2.49 million and -$21.46 million in losses. Loss per share was -$22.40.
| Revenue | 2.49M |
| Gross Profit | -15.63M |
| Operating Income | -21.64M |
| Pretax Income | -21.46M |
| Net Income | -21.46M |
| EBITDA | -21.57M |
| EBIT | -21.64M |
| Loss Per Share | -$22.40 |
Full Income StatementBalance Sheet
The company has $3.09 million in cash and $843,170 in debt, with a net cash position of $2.24 million or $0.78 per share.
| Cash & Cash Equivalents | 3.09M |
| Total Debt | 843,170 |
| Net Cash | 2.24M |
| Net Cash Per Share | $0.78 |
| Equity (Book Value) | 3.83M |
| Book Value Per Share | 2.21 |
| Working Capital | 3.38M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$21.47 million and capital expenditures -$27,612, giving a free cash flow of -$21.50 million.
| Operating Cash Flow | -21.47M |
| Capital Expenditures | -27,612 |
| Depreciation & Amortization | 68,756 |
| Net Borrowing | n/a |
| Free Cash Flow | -21.50M |
| FCF Per Share | -$7.43 |
Full Cash Flow StatementMargins
| Gross Margin | n/a |
| Operating Margin | -869.34% |
| Pretax Margin | -862.34% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
GeoVax Labs does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -361.94% |
| Shareholder Yield | -361.94% |
| Earnings Yield | -645.27% |
| FCF Yield | -646.38% |
Analyst Forecast
The average price target for GeoVax Labs is $1.00, which is -13.04% lower than the current price. The consensus rating is "Hold".
| Price Target | $1.00 |
| Price Target Difference | -13.04% |
| Analyst Consensus | Hold |
| Analyst Count | 1 |
| Revenue Growth Forecast (5Y) | n/a |
| EPS Growth Forecast (5Y) | n/a |
Stock ForecastsFair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
The last stock split was on January 12, 2026. It was a reverse split with a ratio of 1:25.
| Last Split Date | Jan 12, 2026 |
| Split Type | Reverse |
| Split Ratio | 1:25 |
Scores
GeoVax Labs has an Altman Z-Score of -39.79 and a Piotroski F-Score of 1. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -39.79 |
| Piotroski F-Score | 1 |
